2.3.3 GLP-1, inflammation and the gut microbiome In view of the above, increasing evidence indicates a complex and reciprocal relationship among glucagon-like peptide-1 (GLP-1), gut microbiota, and inflammation
Indeed, in clinical practice, metformin demonstrated a variety of beneficial effects on menstrual disorder, anovulation, androgen excess, insulin resistance, and cardiovascular risk, whereas its weight loss effect is often inconsistent and transient [21, 22]
In the United States, 42.4% of adults meet obesity clinical criteria, while only 2.3% of eligible patients currently receive prescription anti-obesity medication
eGLP-1 showed a markedly lower potency at both human and platypus receptors that was even lower than OXM
You can actually see the medication working One of the most motivating things Stelo users on GLP-1s report is being able to literally see their post-meal spikes shrink over weeks of therapy
Discuss with your healthcare team whether adjustment of other diabetes medications is needed